Dermira reports data from DRM04 phase 3 clinical program
Dermira reported new data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis. New findings found patients treated with DRM04 reported significant improvements in their disease-related QOL versus patients who received vehicle only. October 01, 2016